We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Edgewise Therapeutics Inc | NASDAQ:EWTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.67 | -8.35% | 18.33 | 14.50 | 20.26 | 19.99 | 17.955 | 19.10 | 1,139,404 | 05:00:10 |
| | |
PER
SHARE |
| |
TOTAL
|
| ||||||
Public offering price
|
| | | $ | 11.0000 | | | | | $ | 240,000,002 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.3575 | | | | | $ | 7,800,000 | | |
Proceeds to Edgewise Therapeutics, Inc., before expenses
|
| | | $ | 10.6425 | | | | | $ | 232,200,002 | | |
| Leerink Partners | | |
Wedbush PacGrow
|
|
| | |
Page
|
| |||
Prospectus supplement | | | | | | | |
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-6 | | | |
| | | | S-10 | | | |
| | | | S-12 | | | |
| | | | S-14 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-16 | | | |
| | | | S-20 | | | |
| | | | S-24 | | | |
| | | | S-24 | | | |
| | | | S-24 | | | |
| | | | S-25 | | |
| | |
PAGE
|
| |||
Prospectus | | | | | | | |
| | | | ii | | | |
| | | | 1 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 17 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
|
Public offering price per share
|
| | | | | | | | | $ | 11.00 | | |
|
Net tangible book value per share as of September 30, 2023
|
| | | $ | 4.58 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | | 1.55 | | | | | | | | |
|
As adjusted net tangible book value per share after to this offering
|
| | | | | | | | | | 6.13 | | |
|
Dilution per share to new investors purchasing in this offering
|
| | | | | | | | | $ | 4.87 | | |
Underwriter
|
| |
Number of
Shares |
| |||
Leerink Partners LLC
|
| | | | 16,800,000 | | |
Wedbush Securities Inc.
|
| | | | 5,018,182 | | |
Total
|
| | | | 21,818,182 | | |
| | |
Per Share
|
| |
Total
|
| ||||||
Initial public offering price
|
| | | $ | 11.0000 | | | | | $ | 240,000,002.00 | | |
Underwriting discounts and commissions
|
| | | $ | 0.3575 | | | | | $ | 7,800,000.07 | | |
Proceeds, before expenses, to us
|
| | | $ | 10.6425 | | | | | $ | 232,200,001.93 | | |
| | |
PAGE
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 17 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
|
Leerink Partners
|
| |
Wedbush PacGrow
|
|
1 Year Edgewise Therapeutics Chart |
1 Month Edgewise Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions